利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

567 条记录 (耗时 0.027 秒)

    LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME
    3.
    发明授权
    LONG-ACTING GROWTH HORMONE AND METHODS OF PRODUCING SAME 有权

    公开(公告)号：EP2739298B1

    公开(公告)日：2018-10-03

    申请号：EP12819794.4

    申请日：2012-08-02

    申请人： OPKO Biologics Ltd.

    发明人： FARES, Fuad ,  FIMA, Udi Eyal

    IPC分类号： A61K38/00 ,  A61K38/27

    CPC分类号： C07K14/505 ,  C07K14/59

    摘要： Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.

    METHOD OF PREPARING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE
    4.
    发明公开
    METHOD OF PREPARING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE 审中-公开

    公开(公告)号：EP3325496A1

    公开(公告)日：2018-05-30

    申请号：EP16830775.9

    申请日：2016-07-22

    申请人： Hanmi Pharm. Co., Ltd.

    发明人： MOON, Sun Jin ,  SHIN, Cheong Byeol ,  HONG, Sung Hee ,  KIM, Dae Jin ,  KWON, Se Chang

    IPC分类号： C07K1/107 ,  C07K1/30 ,  C07K19/00

    CPC分类号： A61K47/60 ,  C07K14/52 ,  C07K14/59 ,  C07K14/605 ,  C07K14/62 ,  C07K2319/30

    摘要： Provided is a method of preparing a physiologically active polypeptide conjugate, in which a physiologically active polypeptide and a non-peptidyl polymer are linked to each other via a covalent bond. The method is to improve an overall yield of the physiologically active polypeptide conjugate by improving a reaction of the non-peptidyl polymer and the physiologically active polypeptide, and particularly, the method is to prepare a physiologically active polypeptide conjugate in a high yield by performing a two-step reaction through selective precipitation. The preparation method of the present invention is used to produce a non-peptidyl polymer-physiologically active polypeptide conjugate and a physiologically active polypeptide-physiologically active carrier conjugate in a high yield, and therefore, the method may be used in the development of long-acting formulations of various peptide drugs which maintain in vivo activity at a relatively high level and have remarkably increased blood half-life.

    LIGAND/LYTIC PEPTIDE COMPOSITIONS AND METHODS OF USE
    8.
    发明授权
    LIGAND/LYTIC PEPTIDE COMPOSITIONS AND METHODS OF USE 失效
    配体/淋巴肽组合物和使用方法

    公开(公告)号：EP1878438B1

    公开(公告)日：2017-11-29

    申请号：EP07007839.9

    申请日：1998-03-27

    申请人： BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

    发明人： Enright, Frederick M. ,  Jaynes, Jesse M. ,  Hansel, William ,  Koonce, Kenneth L. ,  McCann, Samuel M. ,  Yu, Wen H. ,  Melrose, Patricia A. ,  Foil, Lane D. ,  Elzer, Philip H.

    IPC分类号： A61K38/16 ,  C07K14/68 ,  C07K14/435

    CPC分类号： C07K7/23 ,  A61K38/00 ,  C07K14/43563 ,  C07K14/575 ,  C07K14/59 ,  C07K19/00 ,  C07K2319/00 ,  C12N15/8257

    摘要： Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes). Lysis of tumor cells is rapid. The two components - the ligand and the lytic peptide - may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

    LONG-ACTING HGH POLYPEPTIDES AND USES THEREOF
    9.
    发明公开
    LONG-ACTING HGH POLYPEPTIDES AND USES THEREOF 审中-公开
    长效HGH多肽及其用途

    公开(公告)号：EP3202779A3

    公开(公告)日：2017-09-06

    申请号：EP17161199.9

    申请日：2007-02-05

    申请人： OPKO Biologics Ltd.

    发明人： Fares, Fuad ,  Fima, Udi Eyal

    IPC分类号： C07K14/00 ,  C07K14/52 ,  C07K14/505 ,  C07K14/575 ,  C12N15/00 ,  C12N5/00 ,  A61K38/00 ,  A61K38/19 ,  A61K38/24 ,  A61K31/00 ,  C07K14/61

    CPC分类号： C07K14/505 ,  A61K38/00 ,  C07K14/555 ,  C07K14/59 ,  C07K14/61 ,  C07K2319/00 ,  C07K2319/31

    摘要： A polypeptide comprising a biological activity, said polypeptide comprising a peptide of interest, a single chorionic gonadotropin carboxy terminal peptide attached to the amino terminus of said peptide, two chorionic gonadotropin carboxy terminal peptides attached to the carboxy terminus of said peptide, wherein said polypeptide is the mature polypeptide wherein the signal peptide has been cleaved from the precursor protein, wherein the amino acid sequence of said precursor protein is set forth in SEQ ID NO: 39, and wherein said peptide of interest is hGH.

    摘要翻译： 包含生物学活性的多肽，所述多肽包含感兴趣的肽，连接于所述肽的氨基末端的单一绒毛膜促性腺激素羧基末端肽，连接至所述肽的羧基末端的两个绒毛膜促性腺激素羧基末端肽，其中所述多肽为 其中信号肽已从前体蛋白质切割的成熟多肽，其中所述前体蛋白质的氨基酸序列如SEQ ID NO：39所示，并且其中所述感兴趣的肽是hGH。

    LONG-ACTING FACTOR VII COAGULATION FACTORS
    10.
    发明公开
    LONG-ACTING FACTOR VII COAGULATION FACTORS 审中-公开
    FAKTOR VII GERINNUNGSFAKTOREN MIT LANGZEITWIRKUNG

    公开(公告)号：EP3130346A1

    公开(公告)日：2017-02-15

    申请号：EP16187710.5

    申请日：2010-07-01

    申请人： OPKO Biologics Ltd.

    发明人： FIMA, Udi Eyal ,  HART, Gili

    IPC分类号： A61K38/36 ,  C07K19/00 ,  C12N15/63 ,  C12N5/10 ,  C12N9/64

    CPC分类号： C07K14/505 ,  C07K14/59 ,  C07K14/745 ,  C07K2319/31

    摘要： A polypeptide consisting of a coagulation factor and one to five human chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation factor, wherein said coagulation factor is Factor VII or Factor VIIa, and wherein the sequence of said CTPs comprises the first 10 amino acids of SEQ ID NO: 4 (i.e., the amino acid sequence SSSSKAPPPS), and optionally, a signal peptide attached to the amino terminus of said coagulation factor. Pharmaceutical compositions comprising the polypeptides and medical uses thereof are also disclosed.

    摘要翻译： 一种由凝血因子和1至5个连接到所述凝血因子的羧基末端的人绒毛膜促性腺激素羧基末端肽（CTP）组成的多肽，其中所述凝血因子是因子VII或因子VIIa，并且其中所述CTP的序列包括 SEQ ID NO：4的前10个氨基酸（即，氨基酸序列SSSSKAPPPS），以及任选的附着于所述凝血因子的氨基末端的信号肽。 还公开了包含多肽的药物组合物及其医疗用途。